Cardiotoxicity in patients with acute myeloid leukaemia following anthracycline‐containing chemotherapy: A population‐based matched cohort study
Authors:
- Rikke Hedegaard JensenRJRikke Hedegaard Jensen
- Christian TeglgaardCTChristian Teglgaard
- Jonas Faartoft JensenJonas Faartoft Jensen
- Joachim BaechJBJoachim Baech
- Claus Werenberg MarcherCMClaus Werenberg Marcher
- Anne Stidsholt RougARAnne Stidsholt Roug
- Daniel Tuyet KristensenDKDaniel Tuyet Kristensen
- Rasmus Froberg BrøndumRBRasmus Froberg Brøndum
- Marianne Tang SeverinsenMSMarianne Tang Severinsen
Open Access
- 21 July 2025
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 207 (4) , 1416-1424
Abstract
Summary: Anthracycline‐containing chemotherapy is associated with cardiovascular diseases (CVDs). While knowledge regarding the extent of cardiotoxicity in adult patients with acute myeloid leukaemia (AML) is sparse, anthracyclines remain a key component in the treatment. To address this, 1379 adult AML patients treated with anthracycline‐containing chemotherapy between 2000 and 2020 were matched to 6895 comparators from the Danish background population and followed for a median of 11.8 and 12.8 years respectively. The risk of congestive heart failure (CHF) was higher in AML patients compared to the comparators throughout the entire follow‐up period with adjusted hazard ratios (HRs) ranging from 15.0 (95% CI: 7.02–32.1) after 3 months to 2.68 (95% CI: 1.67–4.30) after 15 years. The risk of non‐CHF CVD was initially higher in AML patients (adjusted HR: 9.16 [95% CI: 6.61–12.7] after 3 months) but converged to that of the comparators after approximately 10 years. Among AML patients, increasing age and male sex were identified as risk factors of CHF and non‐CHF CVD. In summary, AML patients treated with anthracycline‐containing chemotherapy had an elevated risk of CVD, particularly during the first years after treatment initiation. Increased focus on early detection and cardioprotective strategies may help mitigate the harmful effects of anthracyclines in the future.Keywords
This publication has 42 references indexed in Scilit:
- Sex Differences in the Development of Anthracycline-Associated Heart FailureJournal of Cardiac Failure, 2023
- Statins as preventive therapy for anthracycline cardiotoxicity: a meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2023
- Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell TransplantationClinical Lymphoma Myeloma and Leukemia, 2019
- 2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed Under the Auspices of the ESC Committee for Practice GuidelinesEuropean Journal of Heart Failure, 2016
- Major Cardiac Events and the Value of Echocardiographic Evaluation in Patients Receiving Anthracycline-Based ChemotherapyThe American Journal of Cardiology, 2015
- Review and Meta-Analysis of Incidence and Clinical Predictors of Anthracycline CardiotoxicityThe American Journal of Cardiology, 2013
- Early cardiac outcomes following contemporary treatment for childhood acute myeloid leukemia: A north American perspectivePediatric Blood & Cancer, 2013
- Prevalence and predictors of anthracycline cardiotoxicity in children treated for acute myeloid leukaemia: Retrospective cohort study in a single centre in the United KingdomPediatric Blood & Cancer, 2011
- Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AMLPediatric Blood & Cancer, 2006
- Congestive heart failure in patients treated with doxorubicinCancer, 2003